Skip to main content

Table 3 The signal values of GERD-like symptoms of GLP-1-RAs and DPP-4-Is

From: Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

Class Drug name n11 n1+ ROR (95%CI) IC (95%CI)
GLP-1-RAs (ALL) 36 429 5.61* (3.95–7.96) 2.17* (1.66–2.67)
  dulaglutide 1 20 3.08 (0.41–23.04) 0.56 (−1.57–2.70)
  exenatide 19 122 11.08* (6.75–18.18) 2.70* (2.00–3.41)
  liraglutide 15 278 3.39* (2.00–5.74) 1.49* (0.74–2.24)
  lixisenatide 1 12 5.32 (0.69–41.28) 0.71 (− 1.48–2.91)
DPP-4-Is (ALL) 31 3276 0.54 (0.37–0.77) -0.81 (− 1.34 – −0.29)
  alogliptin 1 345 0.17 (0.02–1.20) − 1.77 (−3.82–0.28)
  anagliptin 0 72
  linagliptin 4 332 0.71 (0.26–1.91) −0.40 (−1.71–0.90)
  omarigliptin 0 2
  saxagliptin 0 70
  sitagliptin 16 1181 0.80 (0.48–1.31) −0.30 (−1.01–0.41)
  teneligliptin 0 98
  trelagliptin 1 19 3.25 (0.43–24.39) 0.58 (−1.56–2.72)
  vildagliptin 9 1189 0.44 (0.23–0.85) −1.07 (−2.00 – −0.15)
  1. GERD gastroesophageal reflux disease, GLP-1-RAs glucagon-like peptide-1 receptor agonists, DDP-4-Is dipeptidyl peptidase-4 inhibitors, n 11 the number of target drug induced GERD-like symptoms, n 1+ the number of target drug induced all adverse events, ROR reporting odds ratio, IC information component
  2. * signal detection
\